Immunotherapy sheds new light to cancer treatment and is satisfied by cancer patients.
However, immunotoxicity, single‐source antibodies, and single‐targeting stratege are …

Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and
tissues to treat cancer. As discussed here, the field has progressed considerably as a result …

An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been
genetically modified (Rigvir) is approved and registered for virotherapy, an active and …

Previously, we described an oncolytic vesicular stomatitis virus variant pseudotyped with the
nonneurotropic glycoprotein of the lymphocytic choriomeningitis virus, VSV-GP, which was …

We reported earlier the delivery of antiangiogenic single chain antibodies by using oncolytic
vaccinia virus strains to enhance their therapeutic efficacy. Here, we provide evidence that …

Oncolytic virotherapy is emerging as a promising approach for the treatment of several
neoplasms. The term “oncolytic viruses” is generally employed to indicate naturally …

Many common neoplasms are still noncurative with current standards of cancer therapy.
More therapeutic modalities need to be developed to significantly prolong the lives of …

Primary liver cancer is a common kind of digestive cancers with high malignancy, causing
745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of …

This article reviews the preclinical research, clinical application and development of
Newcastle disease virus (NDV) in the field of cancer therapy. Based on the distinctive …

Colorectal cancer (CRC) is the most preventable malignancy globally, with a high mortality
rate. Cancer stem cells (CSCs) are found previously in multiple types of cancer; CRC is one …